Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Bristol Myers Squibb

Santa Claus Rally In High Gear For Dow; Tesla Eyes 2024 Growth Phase As China Deliveries Surge

The Dow was up more than 0.3% as was the S&P 500, while the Nasdaq climbed 0.4%. The small-cap Russell 2000 added to recent hefty gains.

Investors Business Daily

Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100%

Bristol Myers Squibb said it would acquire cancer drug developer RayzeBio in a $4.1 billion deal. RYZB stock soared; BMY stock traded slightly lower.

Investors Business Daily

Markets Today: Stocks Modestly Higher in Thin Holiday Trade

Morning Markets March E-Mini S&P 500 futures (ES H24) are up +0.09%, and March Nasdaq 100 E-Mini futures (NQH2 4) are up +0.15%. Stock index futures this morning are modestly higher in thin holiday trade, with markets in Europe and parts of Asia closed for Boxing Day. Stocks are supported...

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Bristol Myers Squibb Acquires Karuna Therapeutics in Billion Deal

Bristol Myers Squibb is set to acquire Karuna Therapeutics in a billion deal, expanding its neuroscience portfolio with the promising antipsychotic dru...

Top News

Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio

Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics, a biopharmaceutical company that has developed a new antipsychotic, in a $14 billion deal

The Independent UK

Bristol's $14 Billion Takeover Of Karuna Pulled A Bevy Of Stocks Higher

Bristol Myers Squibb announced its $14 billion acquisition of Karuna Therapeutics on Friday, sending KRTX stock into the stratosphere.

Investors Business Daily

Developing new medicines for everyone, everywhere, equally

The pharmaceutical industry’s role as healer is sorely diminished if we don’t develop medicines fairly for everyone who needs them.

Fortune

Read news from The Economist, FT, and more,
with one subscription

Bristol Myers Skids After Pushing Back A Key $10 Billion Sales Milestone

Bristol Myers Squibb pushed back sales expectations for its new drugs by a year early Thursday, and BMY stock tumbled.

Investors Business Daily

Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Price

Bristol Myers Squibb offered to buy Mirati Therapeutics for up to $5.8 billion, but MRTX stock tumbled on the lowball price.

Investors Business Daily

Biden names 10 drugs for first negotiations to cut Medicare prices

Government claims prices could fall for 9m seniors but pharma companies claim cost-reduction program is unconstitutional

The Guardian - US

The Unexpected Bad News For Novo's Ozempic In Biden's Drug Negotiations List

Drugs from AbbVie, Bristol and Merck took slots on the list of drugs subject to price cuts. But the pharmaceutical stocks were unmoved.

Investors Business Daily

Rethinking auditing and transparency in the age of A.I.

In today’s world of increasing disclosures, such as ESG and cybersecurity, the responsibility of the internal audit continues to expand and has become even more critical.

Fortune

How health care leaders are leveraging technology in a tumultuous economy

Making health care accessible and equitable is the goal.

Fortune

3 factors driving health care inequality—and ideas for how we can solve it

'The rich get richer, and the poor get poorer. The same is true for health...The underserved get sicker.'

Fortune

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Bristol Myers' Revlimid Takes A 32% Hit As Generics Keep Coming

Bristol's Revlimid took fewer than expected generic hits in the fourth quarter, resulting in a beat and a pop for BMY stock Thursday.

Investors Business Daily

Leading Health Stock With Rising Earnings Estimates Nears Buy Point

This top health stock stands out with its proven year-over-year earnings growth record, increased earnings estimates and hefty 2.7% dividend.

The Street

Bristol Myers Stock Higher As Opdivo, Eliquis Sales Power Q3 Earnings Beat

“Our strong results reflect growth of our in-line and new product portfolios,” said CEO Giovanni Caforio.

Investors Business Daily

Bristol Myers Relies On 'Mature' Products For Narrow Quarterly Beat

Most of Bristol Myers' "mature" products delivered commanding third-quarter performances, an analyst said Wednesday as BMY stock rose.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Street

Dice Therapeutics Aces Psoriasis Study and Stock Surges. What's Next?

Dice Therapeutics shares leaped on positive data for its lead drug candidate. What comes next?

The Street

Bristol Myers Squibb Shakes Up Key Biotech Battleground

The FDA approval of Sotyktu for psoriasis has both ignited and dampened prospects for smaller biotech stocks.

The Street

Bristol Myers Stock Surges After FDA Approves New Plaque Psoriasis Treatment; Amgen Slides

“We believe Sotyktu is a breakthrough in the treatment of patients suffering from moderate-to-severe plaque psoriasis," said Bristol Myers' chief medical officer Samit Hirawat.

Investors Business Daily

S&P 500 Stock Market Winners Today

Oil stocks were S&P 500 winners Monday, including Diamondback Energy. Bristol Myers Squibb was among the big losers.

Benzinga

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck's (NYSE:MRK) lead asset MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with end-stage renal disease (ESRD). Merck shares traded in a range of $89.72 to $90.97 on day volume of 5.2…

Benzinga

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

Bristol Myers Squibb (NYSE:BMY) and 2seventy bio (NASDAQ:TSVT) announced positive topline results from KarMMa-3, a Phase 3 study evaluating Abecma (idecabtagene vicleucel) compared to standard combination regimens in adults with multiple myeloma that is relapsed and refractory. Bristol Myers shares traded in a range of $73.95 to $75.32 on a day volume…

Benzinga

Recap Of Friday's Biotech Catalysts - End of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.